

SYNTHESIS AND ANTIVIRAL ACTIVITY OF SEVERAL N-CONTAINING 5 α -STEROIDS


N. Sh. Nadaraia,^{1*} E. O. Onashvili,¹ M. L. Kakhabrishvili,¹
N. N. Barbakadze,¹ B. Sylla,² and A. Pichette²

A study of the antiviral activity of several new hydrazones and amines and amides of 5 α -steroids that were synthesized by us earlier found highly and moderately active compounds. The structures of the synthesized compounds were proven using IR, PMR, ¹³C NMR, and mass spectral data.

Keywords: 5 α -steroids, synthesis, hydrazides, hydrazones, amines, amides, antiviral activity.

Broad spectra of biological activity make steroids and their derivatives promising for discovering new efficacious drugs [1–3]. The high antibacterial, antiviral, and antitumor activity of hydrazono-, amino-, and amido-derivatives of the androstane, estrane, and cholestane series [4–8] and the expanded scope of their synthetic analogs helped to find new biological properties of these compounds.

In continuation of research on the synthesis of bioactive 5 α -steroids from epiandrosterone **1** [9, 10], a transformation product of tigogenin, hydrazones **2–4** were obtained.



Herein we report results for the antiviral activity of synthesized **2–4** and **7–12** that were previously obtained from androst-2-en-17-one (**5**) and 17 β -amino-5 α -androst-2-ene (**6**) [11–13].

Starting 5 α -androstanolone (**1**) was synthesized by the literature method [14]. Acid-catalyzed condensation of it with hydrazides of 2- and 4-benzyloxybenzoic and 2-furanoic acids produced hydrazones **2–4**. Epiandrosterone **1** was converted into ketone **5** and then into amine **6** or into 17 β -(*N,N*-dimethylamino)-5 α -androst-2-ene (**7**). Amides **8–12**, i.e., 17 β -acetamido-5 α -androst-2-ene (**8**), 17 β -chloroacetyl-amino-5 α -androst-2-ene (**9**), 17 β -diethylaminoacetyl-amino-5 α -androst-2-ene (**10**), 17 β -morpholinoacetyl-amino-5 α -androst-2-ene (**11**), and 17 β -piperazinoacetyl-amino-5 α -androst-2-ene (**12**), were synthesized from aminosteroid **6**.

1) I. Kutateladze Institute of Pharmaceutical Chemistry, Tbilisi State Medical University, Tbilisi, 0159, fax: (99532) 52 00 23, e-mail: nnadaraia@ymail.com; 2) LASEVE, Université Québec à Chicoutimi, Chicoutimi, QC, Canada, G7H 2B1, fax: (1) 418 545 50 12, e-mail: andre_pichette@uqac.ca. Translated from *Khimiya Prirodnikh Soedinenii*, No. 5, September–October, 2016, pp. 728–729. Original article submitted January 21, 2016.

The structures of the synthesized compounds **2**, **3** were proven using IR, PMR, and mass spectra. IR spectra of hydrazones **2** and **3** contained characteristic absorption bands for NH and OH stretching vibrations at 3480–3310 and 3460–3305 cm^{-1} and for amide carbonyl stretching vibrations at 1649 and 1647 cm^{-1} . Characteristic frequencies of C=N bonds were observed at 1601 and 1608; aromatic C=C bonds, 1542 and 1501 cm^{-1} . The C–O ether bond gave bands at 1227 and 1250 cm^{-1} , respectively.

PMR spectra (DMSO-d_6) of **2** and **3** showed resonances for angular 18- CH_3 at δ 0.78 and 0.83 ppm; 19- CH_3 , 0.80 and 0.90 ppm as singlets; 3 α -H, at 3.33 ppm as multiplets; 3 β OH protons, at 3.91 and 3.90 ppm as doublets with $J = 4.5$ and 4.4 Hz, respectively. Benzyloxy methylene protons were found at 5.20 and 5.14 ppm as singlets; aromatic protons, at 6.96–8.10 ppm. Weak-field NH protons appeared at 9.94 and 9.77 ppm, respectively.

The structure of **4** was confirmed by PMR, ^{13}C NMR (in CDCl_3), and mass spectra. The PMR spectrum of **4** had angular 18- CH_3 and 19- CH_3 at 0.84 and 0.94 ppm as singlets; 3 α -H, 3.60 as a multiplet; furan-ring proton, 7.63–6.52 ppm (br); and NH, 8.70 ppm. ^{13}C NMR spectra contained peaks for furan-ring C atoms at 146.5–112.2 ppm; amide C=O and hydrazone C=N, 166.2 and 165.5 ppm, respectively. The molecular ion m/z $[\text{M} + \text{H}]^+$ 399.2 corresponded to $\text{C}_{24}\text{H}_{35}\text{N}_2\text{O}_3$.

Antiviral activity of **2–4** and **7–12** was studied at the National Institute of Allergy and Infectious Diseases (NIAID), University of Utah, USA. Studies on Vero 76 cell culture for poliovirus (strain Type 3, WM-3) showed that **3** had high antiviral activity; hydrazones **2** and **4**, moderate activity. The other steroids **7–12** were inactive. Steroids **7** and **8** exhibited moderate activity against Venezuelan equine encephalitis virus (strain TC-83); amide **12**, weak activity against Sars corona virus (strain Urbani). All other compounds were inactive. Only hydrazone **3** showed weak activity against Rift Valley fever virus (Vero 76 cell culture, strain MP-12); only **4**, against Respiratory syncytial virus (MA-104 cell culture, strain A-2). Compounds **2–4** and **7–12** were inactive against Influenza A virus H_1N_1 , Takaribe virus, and Dengue virus (MDCK, Vero, Vero 76 cell cultures; strains California 07.2009, TRVL-11573, and Type-2, NewGuinea C, respectively).

EXPERIMENTAL

PMR were recorded in DMSO-d_6 and CDCl_3 with SiMe_4 internal standard on a Bruker Avance 400 spectrometer (400.13 MHz). IR spectra were taken from KBr pellets on a Varian 660 FT-IR spectrometer. Mass spectra were obtained on an Agilent 1100 series HPLC-APCIMS (positive mode) using an Inertsilprep-ODS column (6.0 \times 250 mm) with elution by H_2O –MeCN (20:80). Melting points were determined on a Nagema apparatus. The course of reactions and purity of synthesized compounds were monitored by TLC on Silufol UV254 plates (Kavalier, Czechoslovakia) using C_6H_6 – Me_2CO (4:1, 10:1). Chromatograms were detected by phosphomolybdic acid solution (10%) in EtOH followed by heating.

General Method for Synthesizing 17-Hydrazone Derivatives of 5 α -Androstan-3-ols 2–4. A mixture of **1** (0.1 g, 0.35 mmol) and the appropriate hydrazide (0.55 mmol) in EtOH (10 mL) with a catalytic amount of AcOH was refluxed for 6–10 h and cooled to room temperature. The resulting precipitate was filtered off, rinsed with H_2O and Et_2O , dried, and crystallized from EtOH.

5 α -Androstan-3 β -ol-17-one 2-Benzyloxybenzoylhydrazone (2). Yield 70%, mp 232–233°C. IR spectrum (KBr, v , cm^{-1}): 3480–3310 (NH, OH), 1649 (NHC=O), 1601 (C=N), 1542 (C=CAr), 1227 (C–O eth.). ^1H NMR spectrum (DMSO-d_6 , δ , ppm, J/Hz): 0.78 (3H, s, 18- CH_3), 0.80 (3H, s, 19- CH_3), 3.33 (1H, m, H-3), 3.91 (1H, d, $J = 4.5$, OH), 5.20 (2H, s, OCH_2), 7.09 (1H, t, $J = 7.5$, H-Ar), 7.23 (1H, d, $J = 8.3$, H-Ar), 7.34–7.56 (6H, m, H-Ar), 8.10 (1H, dd, $J = 7.8, 1.8$, H-Ar), 9.94 (1H, s, NH). LC-MS, m/z $[\text{M} + \text{H}]^+$ 515.3. $\text{C}_{33}\text{H}_{42}\text{N}_2\text{O}_3$, MM 514.3.

5 α -Androstan-3 β -ol-17-one 4-Benzyloxybenzoylhydrazone (3). Yield 73%, mp 210–212°C. IR spectrum (KBr, v , cm^{-1}): 3460–3305 (NH, OH), 1647 (NHC=O), 1608 (C=N), 1501 (C=CAr), 1250 (C–O eth.). ^1H NMR spectrum (DMSO-d_6 , δ , ppm, J/Hz): 0.83 (3H, s, 18- CH_3), 0.90 (3H, s, 19- CH_3), 3.33 (1H, m, H-3), 3.90 (1H, d, $J = 4.4$, OH), 5.14 (2H, s, OCH_2), 6.96 (2H, m, C_6H_4), 7.25–7.44 (5H, m, C_6H_5), 7.80 (2H, m, C_6H_4), 9.77 (1H, s, NH). LC-MS, m/z $[\text{M} + \text{H}]^+$ 515.3. $\text{C}_{33}\text{H}_{42}\text{N}_2\text{O}_3$, MM 514.3.

5 α -Androstan-3 β -ol-17-one 2-Furanylhydrazone (4). Yield 62%, mp 240–242°C. ^1H NMR spectrum (CDCl_3 , δ , ppm, J/Hz): 0.84 (3H, s, 18- CH_3), 0.94 (3H, s, 19- CH_3), 3.60 (1H, m, H-3), 6.52 (1H, br.s, H-4' fur.), 7.48 (1H, br.s, H-3' fur.), 7.63 (1H, br.s, H-5' fur.), 8.70 (1H, br.s, NH). ^{13}C NMR spectrum (CDCl_3 , δ , ppm): 12.2, 16.8, 20.6, 23.2, 25.9, 28.4, 31.4, 31.6, 33.8, 34.8, 35.0, 35.5, 36.8, 38.0, 44.7, 53.3, 54.4, 71.1 (C-3), 112.2 (C-4' fur.), 116.8 (C-3' fur.), 143.7 (C-5' fur.), 146.5 (C-2' fur.), 165.8 (C=N), 166.2 (C=O). LC-MS, m/z $[\text{M} + \text{H}]^+$ 399.2. $\text{C}_{24}\text{H}_{34}\text{N}_2\text{O}_3$, MM 398.2.

REFERENCES

1. A. H. Banday, S. A. Shameem, and S. Jeelani, *Steroids*, **92**, 13 (2014).
2. N. Deive, J. Rodriguez, and C. Jimenez, *J. Med. Chem.*, **44** (16), 2612 (2001).
3. M. I. Choudhary, M. S. Alam, A. Rahman, S. Yousuf, Y. C. Wu, A. S. Lin, and F. Shaheen, *Steroids*, **76**, 1554 (2011).
4. C. Gan, J. Cui, Sh. Su, Q. Lin, L. Jia, L. Fan, and Y. Huang, *Steroids*, **87**, 99 (2014).
5. Y. Huang, J. Cui, L. Jia, C. Gan, H. Song, C. Zeng, and A. Zhou, *Molecules*, **18**, 7436 (2013).
6. J. Cui, L. Liu, D. Zhao, C. Gan, X. Huang, Q. Xiao, B. Qi, L. Yang, and Y. Huang, *Steroids*, **95**, 32 (2015).
7. M. I. Merlani, L. Sh. Amiranashvili, E. P. Kemertelidze, and K. G. Mulkidzhanyan, *Chem. Nat. Compd.*, **45**, 389 (2009).
8. S. D. Taylor and J. Harris, *Steroids*, **76**, 1098 (2011).
9. M. I. Sikharulidze, N. Sh. Nadaraia, M. L. Kakhbrishvili, N. N. Barbakadze, and K. G. Mulkidzhanyan, *Chem. Nat. Compd.*, **46**, 493 (2010).
10. M. I. Sikharulidze, N. Sh. Nadaraia, and M. L. Kakhbrishvili, *Chem. Nat. Compd.*, **48**, 423 (2012).
11. M. I. Merlani, M. G. Davitishvili, N. Sh. Nadaraia, M. I. Sikharulidze, and K. Papadopulos, *Chem. Nat. Compd.*, **40**, 144 (2004).
12. M. I. Sikharulidze, N. Sh. Nadaraia, M. L. Kakhbrishvili, and N. N. Barbakadze, *Sb. Tr. Tbilissk. Gos. Med. Univ.*, **46**, 148 (2012).
13. N. Sh. Nadaraia, M. L. Kakhbrishvili, N. N. Barbakadze, and M. I. Sikharulidze, *Khim. Zh. Gruz.*, **13** (1), 146 (2013).
14. N. I. Men'shova, N. A. Korzinkina, E. P. Kemertelidze, N. Sh. Nadaraia, M. G. Davitishvili, L. I. Lishcheta, and V. S. Grosheva, *Sb. Nauchn. Tr. VNIKhFI*, **10**, 83 (1982).